Adjuvant and antitumor activities of synthetic 6-0-"mycoloyl"-N-acetylmuramyl-L-alanyl-D-isoglutamine were examined. All the synthetic 6-0-corynomycoloyl-, 6-0-nocardomycoloyl-, and 6-0-mycoloyl-N-acetylmuramyl-L-alanyl-D-isoglutamine were active as adjuvants for cell-mediated immune responses. However, 6-0-mycoloyl-N-acetylmuramyl-L-alanyl-D-isoglutamine was less active as an adjuvant on circulating antibody formation. It was shown that pyrogenic activity of N-acetylmuramyldipeptide was reduced by 6-0-acylation with mycolic acid, but not with nocardomycolic or corynomycolic acid. Tumor-suppression activity was observed by the synthetic 6-0-mycoloyl-N-acetylmuramyl-L-alanyl-D-isoglutamine by using transplantable tumor in syngenic mice.
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It has been reported that synthetic N-acetylmuramyldipeptide, i.e., N-acetylmuramyl-Lalanyl-D-isoglutamine, is the minimum adjuvant-active structure in peptidoglycan of bacterial cell walls (7, 11) . The results of an immunological study on N-acetylmuramyl-L-alanyl-D-isoglutamine and 6-0-stearoyl-N-acetylmuramyl-L-alanyl-D-isoglutamine indicated that these synthetic N-acetylmuramyldipeptides were adjuvant-active for the induction of delayed-type hypersensitivity to ABA-N-acetyltyrosine and for the circulating antibody formation to bacterial a-amylase (BaA). However, they were inactive as adjuvants on cell-mediated cytotoxicity in allogenic mice (4) . It also has been shown that N-acetylmuramyl-L-alanyl-D-isoglutamine and 6-0-stearoyl-N-acetylmuramyl-Lalanyl-D-isoglutamine show no antitumor activity on transplantable tumor systems in syngenic mice (4, 9) .
More recently, we synthesized 6-0-mycoloyl-N-acetylmuramyl-L-alanyl-D-isoglutamine, which is more lipophilic than N-acetylmuramyl-L-alanyl-D-isoglutamine or 6-0-stearoyl-N-acetylmuramyl-L-alanyl-D-isoglutamine (13) , and compared its adjuvant activity with that of the Mycobacterium bovis BCG-cell wall skeleton, N-acetylmuramyl-L-alanyl-D-isoglutamine and 6-O-stearoyl-N-acetylmuramyl-L-alanyl-D-iSoglutamine (17) . The results obtained in the previous study indicated that 6-0-mycoloyl-N-acetylmuramyl-L-alanyl-D-isoglutamine was active as an adjuvant on cellular immune response such as induction of cell-mediated cytotoxicity to mastocytoma P815-X2 in allogenic mice, but less effective on the humoral immune response or on the function of helper T cells (17) . From the above-mentioned data we concluded that the mycolic acid moiety introduced into the N-acetylmuramyldipeptide molecule modifies qualitatively the adjuvant activity on immune responses, predominantly on the cellular immune response.
In this study, we compared the adjuvant and antitumor activities of three kinds of "mycoloyl" derivatives of N-acetylmuramyldipeptides ( Fig.  1) , namely, 6-0-nocardomycoloyl-N-acetylmuramyl-L-alanyl-D-isoglutamine, 6-0-corynomycoloyl -N-acetylmuramyl -L -alanyl -D -isoglutamine, and 6-0-mycoloyl-N-acetylmuramyl-Lalanyl-D-isoglutamine, particularly in reference to their chain lengths of mycolic acid residues.
MATERIALS AND METHODS
Synthetic peptides and other adjuvants. Syntheses and properties of N-acetylmuramyl-Lalanyl-D-isoglutamine and 6-0-mycoloyl-N-acetylmuramyl-L-alanyl-D-isoglutamine were reported in previous papers (13, 14) . The chemical syntheses of 6-0-nocardomycoloyl -N-acetylmuramyl-L-alanyl-D -isoglutamine (6-0-nocardomycoloyl-N-acetylmuramyldipeptide) and 6-0-corynomycoloyl-N-acetylmuramyl-L-alanyl-D-isoglutamine (6-0-corynomycoloyl-Nacetylmuramyldipeptide) were carried out by a method similar to that described for 6-0-mycoloyl-Nacetylmuramyldipeptide (13) , and the details will be published soon elsewhere. The nocardomycolic and corynomycolic acids used for the esterification of Nacetylmuramic acid residue were isolated from the cells of Nocardia asteroides strain 131 and Corynebacterium diphtheriae strain PW8, respectively (2). The cell wall skeletons of M. bovis BCG (3) and N. rubra (5) were prepared by methods described previously. The average molecular formulas of "mycolic acid" analogs are described in Table 1 (8) .
Cell-mediated cytotoxicity test. Inbred C57BL/6J mice (H-2b) were immunized intraperitoneally with viable cells of mastocytoma P815-X2 (H2d) with or without 6-O-mycoloyl-N-acetylmuramyl-L-alanyl-D-isoglutamine suspended in PBS. On day 11 after immunization, the cell-mediated cytotoxicity assay was carried out by using the spleen cells of im- Determination of pyrogenic activity. Pyrogenic activity of synthetic N-acetylmuramyldipeptide and its acylated derivatives was determined by the method of The Pharmacopeia ofJapan, 9th ed. (15a). Briefly, the test specimen was dissolved or suspended in pyrogen-free physiological saline at an appropriate concentration. A 10-ml volume of the solution or suspension containing the required dose was injected intravenously into rabbits weighing 1 to 2.7 kg, and rectal temperatures were measured continuously with an automatic body temperature-recording device. When at least two out of three rabbits tested showed individual rises in temperature of 0.6°C or more above their control temperatures, the test specimen was considered pyrogenic. When none of the three rabbits showed such a rise in temperature, the test material was regarded as nonpyrogenic. On the other hand, when one out of the three rabbits showed a temperature rise of 0.6°C or more, or when the sum of the temperature rises exceeded 1.4°C, even if neither one was over 0.6°C, the test materials were judged weakly or doubtfully pyrogenic. 
RESULTS
Adjuvant activity of 6-0-"mycoloyl"-Nacetylmuramyldipeptides on delayed-type hypersensitivity to ABA-N-acetyltyrosine. Hartley strain guinea pigs were immunized with FIA containing 50,ug of ABA-N-acetyltyrosine dissolved in PBS with or without synthetic Nacetylmuramyldipeptides or 6-0-"mycoloyl"-Nacetylmuramyldipeptides as a water-in-oil emulsion. Two weeks later, skin tests with ABA-BaA were done. N-acetylmuramyl-L-alanyl-D-isoglutamine, 6-0-"mycoloyl"-N-acetylmuramyl-L-alanyl-D-isoglutamines, and BCG-cell wall skeleton showed the potent adjuvant activity for the induction of delayed-type hypersensitivity to ABA-N-acetyltyrosine in guinea pigs (Table   2) .
Adjuvant activity on helper T-cells in guinea pigs. After skin testing with ABA-BaA, guinea pigs were immunized with 1 mg of DNPe-Acp-(ABA)-Tyr and 200 ,ug of BCG-cell wall skeleton in FIA. Anti-DNP antibody in sera was determined at 14 and 21 days after secondary immunization. As shown in Table 2 'On day 16 (Table 7) . However, all these synthetic 6-0-mycoloyl-N-acetylmuramyldipeptides suspended in PBS solution were inactive in this tumor system.
DISCUSSION
In a previous paper (17) , we reported that 6-
glutamine is a potent adjuvant on the cell-mediated immune response such as induction of delayed-type hypersensitivity to ABA-N-acetyltyrosine in guinea pigs and generation of effector cells to mastocytoma P815-X2 in allogenic mice, but not on the circulating antibody formation to SRBC and DNP-Lys-Ficoll. In this experiment, the immunological properties of acyl derivatives of N-acetylmuramyldipeptides in which the 6-hydroxy group of muramic acid was esterified with mycolic acid, nocardomycolic acid, or cor- 
glutamines showed adjuvant activities on the generation of effector cells to mastocytoma P815-X2 in C57BL/6J mice; especially 6-0-nocardomycoloyl-N-acetylmuramyl-L-alanyl -Disoglutamine showed the most potent adjuvant activity in this system (Table 3) .
We showed that 6-0-mycoloyl-N-acetylmuramyl-L-alanyl-D-isoglutamine was inactive as an adjuvant on the circulating antibody formation to SRBC and DNP-Lys-Ficoll in mice (17). 6-O-corynomycoloyl-N-acetylmuramyl-Lalanyl-D-isoglutamine was active as an adjuvant on the 19S-PFC formation, although the activity was diminished by acylation with corynomycolic acid compared with that of N-acetylmuramyl-L-alanyl-D-isoglutamine (Table 4 ). In the case of 6-0-nocardomycoloyl-N-acetylmuramyl-Lalanyl-D-isoglutamine, adjuvant activity was less pronounced.
More recently, the correlation between pyrogenicity and adjuvant activity of 14 different Nacetylmuramyldipeptides and amino acids was examined by Kotani et al. (12) . They concluded that there was an almost perfect correlation between the pyrogenicity and adjuvant activity of N-acetylmuramyldipeptide derivatives. The pyrogenic activity ofN-acetylmuramyl-L-alanyl-D-isoglutamine was observed in rabbits (Table  5) , as reported by Kotani et al. 6-0-acylation of N-acetylnuramyl-L-alanyl-D-isoglutamine with stearic, corynomycolic, and nocardomycolic acids did not diminish the pyrogenicity in rabbits. In contrast, 6-0-mycoloyl-N-acetylmuramyl-L-alanyl-D-isoglutamine has no pyrogenic activity even at a dose of 875 ,tg/kg.
From the above results, it may be concluded that pyrogenic activity of N-acetylmuramyldipeptide derivatives does not necessarily correlate directly with their adjuvant activities, at least for cell-mediated immunity.
The antitumor activity of 6-0-"mycoloyl"-Nacetylmuramyl-L-alanyl-D-isoglutamines was examined in fibrosarcoma in SWM/Ms mice. All of the 6-0-"mycoloyl"-N-acetylmuramyl-Lalanyl-D-isoglutamine attached to oil droplets was active for the suppression of fibrosarcoma in SWM/Ms mice (Table 7) ; however, these 6-O-"mycoloyl"-N-acetylmuramyldipeptides suspended in PBS were inactive in this tumor system. 6-0-mycoloyl-N-acetylmuramyl-L-alanyl-D-isoglutamine and 6-0-nocardomycoloyl-Nacetylmuramyl-L-alanyl-D-isoglutamine slightly prolonged survival time of C57BL/6J mice with experimental pleural effusion of fibrosarcoma (T. Yoshimoto et al., unpublished data). Although synthetic 6-0-mycoloyl-N-acetylmuramyl-L-alanyl-D-isoglutamines have potent adjuvant activity, especially on cell-mediated immunity, the antitumor activity of these compounds was less than that of the oil-attached cell wall skeleton ofM. bovis BCG and N. rubra.
The details of antitumor activity of these 6-0-"mycoloyl"-N-acetylmuramyldipeptides are well described in another paper (I. Azuma et al., manuscript in preparation). The synthesis of other acyl analogs of N-acetylmuramyldipeptide having adjuvant and antitumor activities is in progress. 
